Human LIMD1 Alexa Fluor® 488-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: LIMD1

Human LIM Domain-containing Protein 1 (LIMD1) is a ubiquitous tumor suppressor 72 kDa protein which has three LIM zinc-binding domains. Via its LIM domains LIMD1 interacts with TRAF6, SNAI2/SLUG  and SCRT1 (via SNAG domain) proteins. It also interacts with SQSTM1 and RB1, EIF4E, AGO1, AGO2, DCP2, DDX6, LATS1, LATS2, EGLN1/PHD2, EGLN2/PHD1 and EGLN3/PHD3 proteins. LIMD1 interacts with isoform 1 and isoform 3 of VHL and with SNAI1 proteins. LIMD1 localized predominantly in the cytoplasm but shuttles between cytoplasm and nucleus where it can be often detected: strong nuclear expression is indicative for a low-tumor grade and a better patient prognosis. Down-regulation  of LIMD1 is in the nuclei of neoplastic cells, is the indication for a poor prognosis of breast cancer. The correlation exists between LIMD1 and IRF4 in cell lines derived from lymphomas. In ulcerative epithelium it was found that LIMD1 has a reduced nuclear expression. LIMD1 is encoded at chromosome 3p21.3, a region which is deleted in many solid tumors and LIMD1 is down-regulated in the majority of human lung cancer samples. LIMD1 also is a regulator of both bone osetoclast and bone osteoblast development and function. Human LIMD1 shares 77% aa sequence identity with both rat and mouse LIMD1.         

Product Datasheets

Related Research Areas

• Actin Stress Fibers and Focal Adhesions During EMT
• Focal Adhesions
• Wnt Signaling Modulators